By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Alere has licensed the worldwide marketing rights to VitaPath Genetics' spina bifida risk assessment assay, the companies announced Wednesday.

The deal also gives Alere the right to develop with Foster City, Calif.-based VitaPath additional product line extensions mainly focusing on fetal health.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.